Overview
On 21 July 2026, the Union Health Ministry announced that India has granted its first marketing authorisation for a dengue vaccine. The approval was given by the CDSCO for the Qdenga. The vaccine will be imported by Takeda Biopharmaceuticals India Pvt. Ltd. and is intended for people aged 4 to 60 years.
Key Developments
- Marketing authorisation granted after a thorough evaluation under the Drugs and Cosmetics Act, 1940 and Drugs Rules, 1945.
- Vaccine is a live, attenuated tetravalent formulation produced in Vero cells.
- Two sub‑cutaneous doses of 0.5 ml each, given three months apart (0 and 3 months).
- Regulatory approval already secured in 42 countries and has WHO prequalification.
- Post‑marketing data from >24 million doses worldwide show a favourable safety profile.
Important Facts
The vaccine contains genetically modified organisms (GMOs) and is supplied as a freeze‑dried powder for reconstitution. Clinical development involved a global programme across more than eight countries, including Brazil, Thailand and Sri Lanka. A pivotal Phase III study in India evaluated safety and immunogenicity in the target age group.
Exam Relevance
Understanding the role of the NVBDCP is essential for GS‑3 questions on public‑health policy. The approval illustrates how regulatory mechanisms, international cooperation (WHO prequalification), and indigenous clinical trials intersect with India’s health security strategy.
Way Forward
Implementation will require integration with existing dengue control measures: vector control, early diagnosis, and case management under the NVBDCP. States will need to plan cold‑chain logistics for the freeze‑dried vaccine, train health workers for sub‑cutaneous administration, and conduct public awareness campaigns to improve uptake. Continuous post‑marketing surveillance will be crucial to monitor safety and effectiveness in the Indian population.